Cambridge, Massachusetts-based Constellation Pharmaceuticals Inc, a developer of tumor-targeted and immuno-oncology therapies, has raised $60 million for its IPO after pricing its 4 million shares at $15 per share. The stock began trading July 19, 2018 on the NASDAQ under the ticker symbol “CNST.” J.P. Morgan, Jefferies and BMO Capital Markets are the lead underwriters. The investors included Cormorant Asset Management, Deerfield Management, Fidelity Management and Research Company, Hillhouse Capital, NS Investment, OrbiMed, Sirona Capital, Venrock Healthcare Partners, The Column Group, Third Rock Ventures, Venrock, SROne, University of California Investment Office, Topspin Partners and Casdin Capital.
CAMBRIDGE, Mass., July 18, 2018 (GLOBE NEWSWIRE) — Constellation Pharmaceuticals, Inc. (the “Company”)(Nasdaq:CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced the pricing of its initial public offering of 4,000,000 shares of common stock at a public offering price of $15.00 per share, for gross proceeds of $60.0 million, before underwriting discounts and commissions and estimated offering expenses payable by the Company. In addition, the Company has granted the underwriters a 30-day option to purchase up to 600,000 additional shares of common stock at the initial public offering price, less underwriting discounts and commissions. All shares are being offered by the Company.
The Company’s common stock is expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “CNST” on July 19, 2018. The offering is expected to close on July 23, 2018, subject to customary closing conditions.
J.P. Morgan, Jefferies and BMO Capital Markets are acting as joint book-runners for the offering, and Oppenheimer & Co. is acting as co-manager for the offering.
About Constellation Pharmaceuticals
Constellation Pharmaceuticals is a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics that address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance.
Take your pick!
- Buyouts delivers exclusive news and analysis about private equity deals, fundraising, top-quartile managers and more. Get your FREE trial or subscribe now.
- VC Journal provides exclusive news and analysis about venture capital deals, fundraising, top-quartile investors and more. Get your FREE trial or subscribe now.